Pharmaceutical Sales Company Deploys 2020 Work
Release time:
2020-07-15
On January 6, Jianfeng Pharmaceutical Sales Company held its 2019 annual work conference to summarize the gains and losses of 2019 and deploy the work in 2020.
The theme of this conference is "Adapt to the reform and build a system, ensure the sales volume and grasp the terminal, build a strong brand team, and take on the responsibility of grasping the management". Zhou Wenyi, general manager of the pharmaceutical sales company, opened the meeting with "the medical insurance bureau leads the medical reform, and the three medical linkage is smooth". He reviewed the policies for 2019 from the aspects of medicine, medical treatment and medical insurance respectively, and summarized the overall situation of pharmaceutical sales from the aspects of operation, main work development and existing problems, the work in 2020 has been arranged for system improvement, price system, market support, e-commerce and personnel management. After that, the key account manager, terminal sales and commission department held a summary meeting in three venues to summarize the work of the previous year and exchange the work plan for the new year. In the commission section, Zhang Jinhui, deputy general manager of the sales company, elaborated in detail from the aspects of online platform sales management, types of commercial sales control, terminal sales control pairs, profit model, sodium hyaluronate eye drops and other major product work directions, introduced the overall plan of the commission system in 2020, and read out the sales target decomposition plan and assessment criteria of the commission department in 2020. The key account manager and the terminal sales section also summarized the business completion and existing problems of the previous year, and arranged the main work directions for 2020, such as team building, marketing promotion and marketing innovation. Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, and Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, attended the meeting and put forward requirements for sales work. Huang Jinlong analyzed the current situation from many aspects. He hoped that the sales staff would unswervingly support the commission system and control sales mode, stabilize large customers, smoothly transition small customers to commission mode, and ensure product quality. Improve internal management, standardize operation, and truly grow together with enterprises. Jiang Xiaomeng commented on the sales work and asked the pharmaceutical sales company to maintain the resources of major customers. Do a good job in the increment of original products and the quantity of new products; Increase the share of regional hospitals; Sales staff have confidence in the company's products and their own abilities, and constantly improve their business ability and personal accomplishment to adapt to market changes. Sales management personnel should do a good job in service and control to improve profitability.
Prior to this, the pharmaceutical sales company also selected the annual advanced collectives and individuals based on the completion of the responsibility system, and commended them at the meeting. (Ni Yingzhen, Fang Wentong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page